Sugi Predict

Sugi Predict / Compounds / SCHEMBL1014348

SCHEMBL1014348

SCHEMBL1014348

CNS(=O)(=O)c1cccc(CN)c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 4/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ TNNI3K Q59H18 5/20 0.46
▸ BRAF P15056 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ EGFR P00533 1/20 0.45
▸ CYP19A1 P11511 2/20 0.45
▸ LOXL2 Q9Y4K0 1/20 0.44
▸ LMNA P02545 1/20 0.43
▸ PSIP1 O75475 1/20 0.43
▸ CYP4F2 P78329 1/20 0.43
▸ CYP4A11 Q02928 1/20 0.43
▸ KMT2A Q03164 1/20 0.42
▸ ADAMTS4 O75173 1/20 0.42
▸ PRMT1 Q99873 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4636143 0.98 HTR6 (0.54) HTR6L3MBTL1TNNI3KBRAFGAA
SCHEMBL12217548 0.84 KAT6A (0.49) HTR6L3MBTL1TNNI3KGAASMN1; SMN2
SCHEMBL4671611 0.83 HTR6 (0.53) HTR6CYP19A1LOXL2PSIP1KMT2A
SCHEMBL4615715 0.83 HTR6 (0.53) HTR6SMN1; SMN2CYP19A1LMNAPSIP1
SCHEMBL2462774 0.82 L3MBTL1 (0.47) HTR6L3MBTL1TNNI3KGAASMN1; SMN2
SCHEMBL3060871 0.82 L3MBTL1 (0.47) HTR6L3MBTL1TNNI3KGAASMN1; SMN2
SCHEMBL22070843 0.82 L3MBTL1 (0.47) HTR6L3MBTL1TNNI3KGAASMN1; SMN2
SCHEMBL5293352 0.82 IKBKB (0.48) L3MBTL1TNNI3KGAASMN1; SMN2EGFR
SCHEMBL1134875 0.81 CA9 (0.59) HTR6L3MBTL1GAASMN1; SMN2LMNA
SCHEMBL10273897 0.81 KAT6A (0.51) HTR6L3MBTL1TNNI3KGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112939417-B Activated sludge conditioner for wastewater biochemical treatment and preparation method thereof 杭州楠大环保科技有限公司 2022-08-23 — — CN claimed
CN-112939417-A Activated sludge conditioner for biochemical treatment of wastewater and preparation method thereof 杭州楠大环保科技有限公司 2021-06-11 — — CN claimed
EP-1937652-B1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMA INC (US) 2014-07-30 — — EP claimed
WO-2025021943-A1 QUINAZOLINONE, BENZOXAZINONE AND BENZOXAZEPINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS NEURALIS (BE) 2025-01-30 — — WO disclosed
EP-3452477-B1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B C I PHARMA (BE) 2023-09-13 — — EP disclosed
CN-112939417-B Activated sludge conditioner for wastewater biochemical treatment and preparation method thereof 杭州楠大环保科技有限公司 2022-08-23 — — CN disclosed
US-11236093-B2 Adenine derivatives as protein kinase inhibitors B.C.I. PHARMA (BE) 2022-02-01 — — US disclosed
CN-112939417-A Activated sludge conditioner for biochemical treatment of wastewater and preparation method thereof 杭州楠大环保科技有限公司 2021-06-11 — — CN disclosed
US-20190127379-A1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2019-05-02 — — US disclosed
EP-2271624-B9 IMINOPYRIDINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-11-12 — — EP disclosed
EP-1937652-B1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMA INC (US) 2014-07-30 — — EP disclosed
US-20110034464-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-10 — — US disclosed
EP-2271624-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-01-12 — — EP disclosed
US-20090270393-A1 Iminopyridine Derivatives and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 — — US disclosed
WO-2009131245-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-29 — — WO disclosed
CN-101538246-A Pyrimidine amide compounds as pgds inhibitors AVENTIS PHARMA INC 2009-09-23 — — CN disclosed
CN-101282943-A Pyrimidine amide compounds as PGDS inhibitors AVENTIS PHARMA INC (US) 2008-10-08 — — CN disclosed
US-20080227782-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2008-09-18 — — US disclosed
EP-1937652-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS Aventis Pharmaceuticals Inc. (US) 2008-07-02 — — EP disclosed
WO-2007041634-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2007-04-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227782-A1 PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, LTC4S HTR6 1058/4885L3MBTL1 3101/4885TNNI3K 1346/4885
US-11236093-B2 Adenine derivatives as protein kinase inhibitors ADK, TNNI3K, TNK2 HTR6 2606/4885L3MBTL1 1646/4885TNNI3K 2/4885
US-20190127379-A1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS ADK, TNNI3K, TNK2 HTR6 2606/4885L3MBTL1 1646/4885TNNI3K 2/4885
US-20110034464-A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF ADRA1D, ADRB1, ADRB2 HTR6 377/4885L3MBTL1 3347/4885TNNI3K 3497/4885
US-20090270393-A1 Iminopyridine Derivatives and Use Thereof ADRA1D, ADRB1, ADRB2 HTR6 377/4885L3MBTL1 3347/4885TNNI3K 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.